Thermo Fisher Scientific financials
$679.61+0.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B | $20.92B | $18.27B |
| Gross profit | $18.24B | $17.70B | $17.10B | $18.97B | $19.64B | $16.00B | $11.33B | $10.86B | $9.45B | $8.37B |
| Gross margin | 40.9% | 41.3% | 39.9% | 42.2% | 50.1% | 49.7% | 44.4% | 44.6% | 45.2% | 45.8% |
| Operating income | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $3.78B | $2.96B | $2.46B |
| Net income | $6.70B | $6.33B | $6.00B | $6.95B | $7.72B | $6.38B | $3.70B | $2.94B | $2.23B | $2.02B |
| Net margin | 15.0% | 14.8% | 14.0% | 15.5% | 19.7% | 19.8% | 14.5% | 12.1% | 10.6% | 11.1% |
| Diluted EPS | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 | $15.97 | $9.17 | $7.24 | $5.59 | $5.09 |
| EBITDA | $10.89B | $10.82B | $10.72B | $11.89B | $12.82B | $10.22B | $6.46B | $6.10B | $5.09B | $4.41B |
| Operating cash flow | $7.82B | $8.67B | $8.41B | $9.15B | $9.31B | $8.29B | $4.97B | $4.54B | $4.00B | $3.26B |
| Free cash flow | $6.29B | $7.27B | $6.93B | $6.91B | $6.79B | $6.82B | $4.05B | $3.79B | $3.50B | $2.81B |
| Diluted shares | 378.0M | 383.0M | 388.0M | 394.0M | 397.0M | 399.0M | 403.0M | 406.0M | 398.0M | 397.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.85B | $4.01B | $8.08B | $8.52B | $4.48B | $10.32B |
| Short-term investments | $253.0M | $1.56B | $3.0M | $0.00 | — | — |
| Total debt | $39.38B | $31.27B | $34.92B | $34.49B | $34.87B | $21.73B |
| Total assets | $110.34B | $97.32B | $98.73B | $97.15B | $95.12B | $69.05B |
| Total liabilities | $56.81B | $47.65B | $51.88B | $53.01B | $54.15B | $34.53B |
| Shareholders' equity | $53.41B | $49.55B | $46.72B | $44.03B | $40.85B | $34.52B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology